| Literature DB >> 35487673 |
Xinyu Feng1, Fang Huang1, Jianhai Yin1, Rubo Wang1, Zhigui Xia2.
Abstract
Although the total number of malaria cases and fatalities have declined globally since 2010, there were still 241 million malaria cases identified across 85 countries and territories in 2020. As the global malaria eradication process accelerates, more countries have launched their own initiatives of elimination. Notably, China achieved this goal by 2021, ending thousands of years of endemic. Undoubtedly, tremendous experience and vital lessons have been accrued en route to the malaria-free goal in malaria-eliminated countries including China. To enhance prospects of a malaria-free world by bridging the key evidence from a malaria-eliminated country to the contexts of affected, this personal view highlights concerted commitments and universal investment in healthcare, improved surveillance and response system, constant capacity building, demand-oriented scientific research, and multiway cooperation, which have helped China to eliminate this ancient scourge. We discuss how these key takeaways could be leveraged to different contexts. We also argue the long-term challenges and barriers on the pathway to malaria elimination and underline the needs for consistent efforts to maintain zero indigenous cases and prevent re-introduction of malaria. Through concerted efforts from global collaboration, a malaria-free world can become a reality. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: Malaria
Mesh:
Year: 2022 PMID: 35487673 PMCID: PMC9058700 DOI: 10.1136/bmjgh-2021-008351
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Malaria incidence in China from 1949 to 2020 and major events in the process of eliminating malaria. *According to the epidemiological characteristics of malaria throughout different historical periods, the course of malaria elimination in China could be classified into the following stages: the focal investigation and prevention stage (1949–1959); the severe epidemic stage (1960–1979); the continuous incidence declining stage (1980–1999); the control/pre-elimination stage (2000–2009); and the elimination stage (2010-2020).
Major gaps towards malaria elimination and potential opportunities and actions needed
| Gap | Current state | Desired state | Opportunity | Action needed |
| Malaria control progress staggered and reversed |
Resurgence on morbidity and mortality Malaria is still endemic in 85 countries and territories |
Malaria fatalities declined to a low level Ultimate goal for a malaria-free world |
Over 100 countries have eliminated malaria More countries are moving towards the elimination of malaria Some African countries have eliminated malaria |
Global malaria response back on track Increased and improved coverage of current tools |
| Financial shortage and insufficient government involvement |
Backdrop of financial support with population growth Depending on external funding Lack of governmental support and commitment |
Filling the funding gaps Unwavering commitment of government |
Progress in world economic development, especially in Africa Commitments from national governments, pharmaceutical companies, the Global Fund, and the Bill and Melinda Gates Foundation |
Funding support from the government, private sectors and stakeholders Multilateral cooperation, including both international and subnational |
| Prioritise malaria among all infectious diseases |
Continued gaps in fighting AIDS, tuberculosis, dengue and new emergence diseases Fragile, overwhelmed African health systems The widespread impact of COVID-19 |
Universal health coverage and access to health services An integrated effective health system |
Access to quality of water, sanitation and hygiene conditions Technological advances and innovations in new tools, for example, vaccines |
Prevention of new cases of malaria Revamped health systems To reduce the impact of other diseases on malaria |
| Prevention and treatment |
Insufficient access to bed nets Uncovered protection by indoor residual spray (IRS) Lack access to the tools that prevent, diagnose and treat the disease 70% of all malaria deaths occurred under the age of five Not accessing the WHO-recommended regimens for women and children |
Expanding key interventions’ access to most vulnerable Delivering malaria control tools to those most in need Flexible and tailored strategies to local contexts Ideal vaccine protection |
The WHO Global Malaria Programme put high priority to close gaps in access to proven malaria control tools Increased investment in proven prevention measures Development and deployment of new diagnostic and treatment tools |
Scale-up of effective tools, including expanded access to ITNs, IRS and ACTs More comprehensive analysis on gaps in prevention, diagnostic testing and treatment Seasonal malaria chemoprevention (SMC) for children under 5 years of age Community mobilisation |
| Insecticides and drug resistance |
Developing and spread of insecticide resistance in more than 60 countries Mounting evidences on resistance of parasites to artemisinin derivatives Multidrug-resistant parasites and potential spread |
Available therapeutic antimalarial regimen and effective vector control tools Delay the appearance of insecticide resistance Containing artemisinin resistance in subregional and regional areas |
Supplemented by other vector control methods Geospatial and temporal mapping of the emergence and spread Parallel, robust investments in the research and development of new tools |
Integrated surveillance and monitoring on insecticides and drug resistance To invent active ingredients except pyrethroid To innovate antimalaria drugs To adopt more efficacious treatment regimens |
Primary challenges on the way to malaria elimination and corresponding strategies in China
| Stage (year) | Primary challenges | Strategies coping with challenges |
| The focal investigation and prevention stage (1949–1959) |
High morbidity and mortality Lack of professional agencies Lack of baseline data |
Establish professional agencies Carry out baseline investigation and field trials Initiate National Malaria Control Programme Notifiable disease enrolment |
| The severe epidemic stage (1960–1979) |
Vivax malaria pandemics in central China |
Mass drug administration (MDA) with prophylactic and radical medications Mass protection Initiate intranational cooperation mechanisms |
| The continuous incidence declining stage (1980–1999) |
Severe epidemic in remote areas Unstable epidemic |
Comprehensive measures based on vector habits in receptive areas with different |
| The control/pre-elimination stage (2000–2009) |
Serious under-reporting of malaria High transmission in Yunnan and Hainan in southern China Resurgence and outbreaks in central China |
Strengthen blood test, early diagnosis and appropriate treatment, LLINs (Long-lasting insecticide impregnated nets)/ITNs distribution, health education, and monitoring and evaluation with support from the Global Fund Establish web-based reporting system Target MDA in central China |
| The elimination stage |
Lack of changes in concepts and strategies from control to elimination Border malaria Imported malaria Long-term no malaria case debilitates the health workers’ capacity |
Adaptive case-centric and focus-centric comprehensive strategy and 1-3-7 approach Construction and re-inforcement of elimination-specific reporting system and diagnosis reference laboratory network Three defensive lines strategy and ‘3+1’ strategy in border areas of Yunnan province Imported malaria management through multisectoral cooperation Various capacity-building and maintenance measures |